News | December 30, 2022
Claim against Dr. Reddy’s Laboratories dismissed over Revlimid in US
All claims against the company in the litigation have now been dismissed.
All claims against the company in the litigation have now been dismissed.
The new facility will be able to handle four times as many patients as the previous facility.
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The cash and debt free consideration value is €370 million.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Subscribe To Our Newsletter & Stay Updated
